Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients |
| |
| Authors: | Vajda Alice Marignol Laure Foley Ruth Lynch Thomas H Lawler Mark Hollywood Donal |
| |
| Affiliation: | aInstitute of Molecular Medicine, Trinity Centre for Health Sciences, St James’s Hospital, Dublin 8, Ireland;bDivision of Radiation Therapy, Trinity Centre for Health Sciences, St James’s Hospital, Dublin 8, Ireland;cDepartment Of Urology, St James’s Hospital, Dublin 8, Ireland;dExperimental Haematology/Oncology, School of Medicine, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St James’s Hospital, Dublin 8, Ireland;eClinical Oncology, Head of the Academic Unit of Clinical and Molecular Oncology, Trinity College Dublin, Dublin 2, Ireland |
| |
| Abstract: | Despite the advances in prostate cancer diagnosis and treatment, current therapies are not curative in a significant proportion of patients. Gene-directed enzyme prodrug therapy (GDEPT), when combined with radiation therapy, could improve the outcome of treatment for prostate cancer, the second leading cause of cancer death in the western world. GDEPT involves the introduction of a therapeutic transgene, which can be targeted to the tumour cells. A prodrug is administered systemically and is converted to its toxic form only in those cells containing the transgene, resulting in cell kill. This review will discuss the clinical trials which have investigated the potential of GDEPT at various stages of prostate cancer progression. The advantages of using GDEPT in combination with radiotherapy will be examined, as well as some of the recent advances which enhance the potential utility of GDEPT. |
| |
| Keywords: | Gene-directed enzyme prodrug therapy GDEPT Radiation therapy Prostate cancer |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
